Clinical Trials Logo

Clinical Trial Details — Status: Not yet recruiting

Administrative data

NCT number NCT06230198
Other study ID # TheRAPy
Secondary ID
Status Not yet recruiting
Phase N/A
First received
Last updated
Start date May 2024
Est. completion date March 2025

Study information

Verified date January 2024
Source Population Health Research Institute
Contact TheRAPy Study Coordinator
Phone 9055212100
Email therapy@phri.ca
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The TheRAPy vanguard trial is a multicentre, multiple period randomized, cluster crossover vanguard trial testing the feasibility of a full-scale trial to evaluate whether a centre-based policy of routine use of RAP versus a policy of crystalloid priming reduces RBC transfusion for patients undergoing cardiac surgery on cardiopulmonary bypass. It will also provide information about key parameters of the TheRAPy full-scale trial.


Description:

About 50% of patients undergoing cardiac surgery require red blood cell (RBC) transfusion. Given the limited blood supply and harms of transfusion, evidence-based blood conservation strategies are a priority. There is one such simple conservation technique called Retrograde autologous priming (RAP), in which the patient's own blood, rather than crystalloid fluid, is used to prime the heart-lung machine. Ultimately, it minimizes the loss of RBCs during surgery. Despite evidence of RAP reducing incidence of RBC transfusions by 40% and RBC units transfused by 38% in small randomized trials, it is not routinely used due to the uncertainty about overall benefit and potential harms. Routine RAP may be beneficial, but this needs to be confirmed in a large pragmatic randomized trial. Therefore, the goal of this vanguard trial is to assess the feasibility of a full-scale multi-centre randomized cluster crossover trial to determine whether an institutional policy of routine RAP reduces the number of RBC units transfused up to 72 hours after cardiac surgery compared to crystalloid priming. This will include 4 sites that will test the two policies in an alternating sequence during 12 periods of 4 weeks, with an expected volume of 4500 cardiac surgery patients. If the adherence to both polices is >=90%, a full trial will be conducted. The findings of this study have the potential to improve the outcomes of tens of thousands of patients around the world and will provide the basis for cardiac practice guidelines.


Recruitment information / eligibility

Status Not yet recruiting
Enrollment 4500
Est. completion date March 2025
Est. primary completion date October 2024
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 10 Years to 110 Years
Eligibility Inclusion Criteria: - Hospitals completing >200 adult cardiac surgical cases a year; (ii) 95% of cardiovascular surgery group (i.e., cardiac anesthesiologists, surgeons, and perfusionists) agree to manage patients under both autologous priming policies as per their randomization schedule for the duration of the trial. - All patients undergoing cardiac surgery on cardiopulmonary bypass at an enrolled site during the trial period will be included in data collection. Exclusion Criteria: - 1) Complete <=200 cardiac surgical cases. 2) <95% of their cardiovascular surgery group agrees to manage patients according to either of the two policies.

Study Design


Related Conditions & MeSH terms


Intervention

Procedure:
retrograde autologous priming (RAP)
whether an institutional policy of routine use of retrograde autologous priming (RAP) reduces red blood cell (RBC) transfusion compared to crystalloid priming up to 72 hours after cardiac surgery

Locations

Country Name City State
n/a

Sponsors (1)

Lead Sponsor Collaborator
Population Health Research Institute

Outcome

Type Measure Description Time frame Safety issue
Primary Feasibility of implementing a full-scale randomized cluster crossover trial where feasibility is defined as adherence >90% to both institutional policies applied in random sequence The primary objective is to assess the feasibility of a full-scale randomized cluster crossover trial to determine whether an institutional policy of routine use of retrograde autologous priming (RAP) reduces red blood cell (RBC) transfusion compared to crystalloid priming up to 72 hours after cardiac surgery. We will define feasibility as adherence >90% to both institutional policies applied in random sequence. 6 months
Secondary Critical Parameters to collect data about critical parameters that affect the design and implementation of the full-scale trial 6 months
See also
  Status Clinical Trial Phase
Active, not recruiting NCT03344887 - An Innovative Trial Assessing Donor Sex on Recipient Mortality Phase 4
Recruiting NCT04757909 - Detection of Anemizations in Primary Care. N/A
Terminated NCT02566577 - Physiologic Effects of RBC Transfusion Phase 4
Recruiting NCT04920045 - A Trial to Assess the Effect of Transfusion Strategies on Fatigability Levels After Hospital Discharge N/A
Completed NCT01258010 - Impact of Tranexamic Acid on Red Blood Cell Transfusion in Spinal Surgery N/A
Recruiting NCT05405426 - Trial of Indication-Based Transfusion of Red Blood Cells in ECMO N/A
Completed NCT05798130 - Assessment of Oxygen Extraction Rate Changes Following Red Blood Cell Transfusion in the Intensive Care Unit